Inmune Bio Files 8-K Report
Ticker: INMB · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Jan 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: INMB
TL;DR
INMB filed an 8-K, check for updates on financials/events.
AI Summary
On January 28, 2025, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Inmune Bio, Inc. is providing updates to the SEC, which could contain important information for investors regarding the company's financial health or significant operational developments.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific material disclosures that would immediately impact risk.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- January 28, 2025 (date) — Date of earliest event reported
- 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Inmune Bio, Inc.?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events.
When was the earliest event reported in this filing?
The earliest event reported was on January 28, 2025.
What is Inmune Bio, Inc.'s principal executive office address?
The principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What is Inmune Bio, Inc.'s telephone number?
The registrant's telephone number is (858) 964-3720.
What is Inmune Bio, Inc.'s state of incorporation?
Inmune Bio, Inc. is incorporated in Nevada.
Filing Stats: 460 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-28 16:00:55
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0228960-8k_inmunebio.htm (8-K) — 23KB
- ea022896001ex99-1_inmunebio.htm (EX-99.1) — 17KB
- 0001213900-25-007521.txt ( ) — 215KB
- inmb-20250128.xsd (EX-101.SCH) — 3KB
- inmb-20250128_lab.xml (EX-101.LAB) — 33KB
- inmb-20250128_pre.xml (EX-101.PRE) — 22KB
- ea0228960-8k_inmunebio_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On January 28, 2025, INmune Bio Inc. (the "Company"), issued a press release announcing that the first patient was treated in the Company's phase I/II trial in men with metastatic castration-resistant prostate cancer at the West Los Angeles Veterans Administration Hospital. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated January 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: January 28, 2025 By: /s/ David Moss Name: David Moss Title: Chief Financial Officer 2